Key Highlights

  • The third-quarter net loss reached USD 81.7 million, or USD 0.37 per share, compared with USD 74.1 million, or USD 0.43 per share, a year ago.
  • Cash, cash equivalents and investments stood at USD 848.6 million on September 30, 2026, and management expects that sum to fund operations into 2029.
  • Research and development climbed to USD 77.1 million from USD 68.3 million, and general and administrative expense rose to USD 13.1 million from USD 12.1 million.
  • Nine-month financing brought in USD 296.8 million from a May follow-on offering and USD 159.2 million from at-the-market sales, both on a net basis.

Quarterly Loss Widens as Late-Stage Spending Builds

Relay Therapeutics (NASDAQ:RLAY) is a clinical-stage precision medicine developer. It submitted its Quarterly Report on November 4, 2026, for the period ended September 30, 2026, and reported no Revenue in the quarter. The net loss reached USD 81.7 million. Research and Development totaled USD 77.1 million against USD 68.3 million, while general and administrative costs moved to USD 13.1 million from USD 12.1 million, lifting operating expenses to USD 90.2 million from USD 80.4 million. Nine-month research and development came to USD 224.2 million, and interest income increased to USD 8.5 million from USD 6.4 million. The nine-month net loss was USD 238.7 million, or USD 1.19 per share, with nine-month revenue of USD 3.4 million versus USD 8.4 million. A higher weighted share count, 219.2 million against 172.4 million, explains why the per-share loss shrank. Unrealized Investment losses of USD 3.8 million pushed the comprehensive loss to USD 85.6 million.

Equity Raises Rebuild the Cash Position

Cash rose through Equity issuance rather than operations. In May 2026, the company completed a follow-on offering of 26,354,167 shares that netted USD 296.8 million, and at-the-market sales added another USD 159.2 million net over nine months. Net cash from financing reached USD 466.9 million for the period. Management states that the USD 848.6 million in cash, equivalents and investments will cover operating and Capital Expenditure needs into 2029, though that estimate rests on assumptions that could prove wrong. Additional capital will be needed to keep developing the pipeline and to commercialize any approved drug, and every raise dilutes current holders.

Zovegalisib Phase 3 Sits at the Center of the Story

Relay Therapeutics (NASDAQ:RLAY) is advancing zovegalisib, which it calls the first known allosteric, pan-mutant and isoform-selective PI3Kα inhibitor in clinical development. The global Phase 3 ReDiscover-2 study began in the second quarter of 2025 and compares zovegalisib with fulvestrant against capivasertib with fulvestrant in previously treated HR+/HER2- breast cancer. The FDA granted Breakthrough Therapy Designation in February 2026. In April 2026, the company chose atirmociclib, an investigational drug from Pfizer (NYSE:PFE), as its triplet combination partner. Its Dynamo platform pairs computational and experimental methods to target proteins that were previously hard to address. Other programs include RLY-8161, an NRAS-selective inhibitor in trials for NRAS-mutant melanoma and other solid tumors, a Fabry disease chaperone and a TIE2 inhibitor for vascular anomalies.

Where Things Stand

On management's own estimate, yes, through 2029. Relay Therapeutics (NASDAQ:RLAY) is losing about USD 80 million a quarter (calculated from the USD 238.7 million nine-month loss), so the runway depends on spending holding near current levels and on trial progress. The estimate may prove wrong, the company says it will need more capital, and approval is not assured. The Phase 3 ReDiscover-2 trial is the main event to follow.